Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement. 

Olema launched this year’s 75^th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?